| Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes C Corcoran, S Rani, K O’Brien, A O’Neill, M Prencipe, R Sheikh, G Webb, ... PloS one 7 (12), e50999, 2012 | 493 | 2012 |
| Characterisation and manipulation of docetaxel resistant prostate cancer cell lines AJ O'Neill, M Prencipe, C Dowling, Y Fan, L Mulrane, WM Gallagher, ... Molecular cancer 10, 1-13, 2011 | 220 | 2011 |
| Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors P Parrella, ML Poeta, AP Gallo, M Prencipe, M Scintu, A Apicella, ... Clinical Cancer Research 10 (16), 5349-5354, 2004 | 170 | 2004 |
| The role of epithelial–mesenchymal transition drivers ZEB 1 and ZEB 2 in mediating docetaxel‐resistant prostate cancer K Hanrahan, A O'Neill, M Prencipe, J Bugler, L Murphy, A Fabre, M Puhr, ... Molecular oncology 11 (3), 251-265, 2017 | 130 | 2017 |
| Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression MO Hoque, M Prencipe, ML Poeta, R Barbano, VM Valori, M Copetti, ... Cancer epidemiology, biomarkers & prevention 18 (10), 2694-2700, 2009 | 99 | 2009 |
| Low MAD2 expression levels associate with reduced progression‐free survival in patients with high‐grade serous epithelial ovarian cancer F Furlong, P Fitzpatrick, S O'Toole, S Phelan, B McGrogan, A Maguire, ... The Journal of pathology 226 (5), 746-755, 2012 | 87 | 2012 |
| Genomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinoma M Scintu, R Vitale, M Prencipe, AP Gallo, L Bonghi, VM Valori, E Maiello, ... Cancer letters 254 (2), 298-307, 2007 | 68 | 2007 |
| Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro M Prencipe, P Fitzpatrick, S Gorman, M Mosetto, R Klinger, F Furlong, ... British journal of cancer 101 (11), 1900-1908, 2009 | 55 | 2009 |
| Novel strategies for cancer treatment: highlights from the 55th IACR annual conference S Charmsaz, DM Collins, AS Perry, M Prencipe Cancers 11 (8), 1125, 2019 | 51 | 2019 |
| The role of transcription factors in prostate cancer and potential for future RNA interference therapy KA Fitzgerald, JC Evans, J McCarthy, J Guo, M Prencipe, M Kearney, ... Expert Opinion on Therapeutic Targets 18 (6), 633-649, 2014 | 45 | 2014 |
| HIC1 promoter methylation and 17p13. 3 allelic loss in invasive ductal carcinoma of the breast P Parrella, M Scintu, M Prencipe, ML Poeta, AP Gallo, C Rabitti, M Rinaldi, ... Cancer letters 222 (1), 75-81, 2005 | 38 | 2005 |
| Sub-toxic concentrations of ionic liquids enhance cell migration by reducing the elasticity of the cellular lipid membrane P Kumari, VVS Pillai, BJ Rodriguez, M Prencipe, A Benedetto The Journal of Physical Chemistry Letters 11 (17), 7327-7333, 2020 | 37 | 2020 |
| Innovative technologies changing cancer treatment S Charmsaz, M Prencipe, M Kiely, GP Pidgeon, DM Collins Cancers 10 (6), 208, 2018 | 33 | 2018 |
| Identification of transcription factors associated with castration‐resistance: Is the serum responsive factor a potential therapeutic target? M Prencipe, SF Madden, A O'Neill, G O'Hurley, A Culhane, D O'Connor, ... The Prostate 73 (7), 743-753, 2013 | 27 | 2013 |
| The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases G O'Hurley, M Prencipe, D Lundon, A O'Neill, S Boyce, A O'Grady, ... The Prostate 74 (3), 306-313, 2014 | 22 | 2014 |
| The use of LC‐MS to identify differentially expressed proteins in docetaxel‐resistant prostate cancer cell lines K O'Connell, M Prencipe, A O'Neill, C Corcoran, S Rani, M Henry, ... Proteomics 12 (13), 2115-2126, 2012 | 21 | 2012 |
| Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer B McGrogan, S Phelan, P Fitzpatrick, A Maguire, M Prencipe, D Brennan, ... Human pathology 45 (7), 1509-1519, 2014 | 19 | 2014 |
| Lack of association between genetic variants in the mannose-binding lectin 2 (MBL2) gene and HPV infection P Parrella, D Seripa, MG Matera, M Rinaldi, E Signori, C Gravina, ... European journal of epidemiology 22, 159-162, 2007 | 19 | 2007 |
| The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation DJ Lundon, A Boland, M Prencipe, G Hurley, A O’Neill, E Kay, ST Aherne, ... BMC cancer 17, 1-13, 2017 | 18 | 2017 |
| Commercialized biomarkers: new horizons in prostate cancer diagnostics L Murphy, M Prencipe, WM Gallagher, RW Watson Expert review of molecular diagnostics 15 (4), 491-503, 2015 | 18 | 2015 |
